Еволокумаб (Bulgarian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Еволокумаб" in Bulgarian language version.

refsWebsite

Global rank Bulgarian rank

2^nd place

7^th place

3web.archive.org

1^st place

1^st place

low place

low place

195^th place

125^th place

low place

3,587^th place

low place

low place

447^th place

576^th place

14^th place

176^th place

low place

low place

low place

low place

2,374^th place

615^th place

amgen.ca

Amgen – Media – In The News // www.amgen.ca. Архивиран от оригинала на 2016-03-04. Посетен на 17 септември 2015.

amgen.com

investors.amgen.com

Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA^{[неработеща препратка]}
European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol, архив на оригинала от 22 юли 2015, https://archive.today/20150722065627/http://investors.amgen.com/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2069405, посетен на 28 октомври 2018

archive.today

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol, архив на оригинала от 22 юли 2015, https://archive.today/20150722065627/http://investors.amgen.com/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2069405, посетен на 28 октомври 2018

doi.org

dx.doi.org

Phase 3 data for PCSK9 inhibitor wows // Nature Biotechnology 31 (12). 2013. DOI:10.1038/nbt1213-1057. с. 1057 – 8.
Weinreich, M и др. Antihyperlipidemic therapies targeting PCSK9. // Cardiology in Review 22. 2014. DOI:10.1097/CRD.0000000000000014. с. 140 – 6.
Kazi, Dhruv S. и др. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease // JAMA 316 (7). 16 август 2016. DOI:10.1001/jama.2016.11004. с. 743.
S., Sabatine, Marc et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – NEJM // New England Journal of Medicine. 17 март 2017. DOI:10.1056/nejmoa1615664. (на английски)

fda.gov

FDA approves Repatha to treat certain patients with high cholesterol // 27 август 2015. Посетен на 30 август 2015.

hc-sc.gc.ca

Regulatory Decision Summary (SBD): REPATHA – 2015 – Health Canada // www.hc-sc.gc.ca. Архивиран от оригинала на 2015-10-07. Посетен на 6 октомври 2015.

nejm.org

S., Sabatine, Marc et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – NEJM // New England Journal of Medicine. 17 март 2017. DOI:10.1056/nejmoa1615664. (на английски)

spisaniemd.bg

(PCSK9 инхибитори – нов клас медикаменти за лечение) // Архивиран от оригинала на 2018-10-28. Посетен на 2018-10-28.

web.archive.org

(PCSK9 инхибитори – нов клас медикаменти за лечение) // Архивиран от оригинала на 2018-10-28. Посетен на 2018-10-28.
Regulatory Decision Summary (SBD): REPATHA – 2015 – Health Canada // www.hc-sc.gc.ca. Архивиран от оригинала на 2015-10-07. Посетен на 6 октомври 2015.
Amgen – Media – In The News // www.amgen.ca. Архивиран от оригинала на 2016-03-04. Посетен на 17 септември 2015.

who.int

World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 (PDF) // WHO Drug Information 26 (4). 2012.

wikipedia.org

en.wikipedia.org

Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA^{[неработеща препратка]}